(Q37890777)

24 August 2017

1 reference

title

A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition (English)

1 reference

24 August 2017

0 references

0 references

0 references

Jan Basile

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

24 August 2017

published in

Postgraduate Medicine

1 reference

24 August 2017

volume

123

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

38-45

1 reference

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

The barrier of hypoglycemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Microvascular complications of impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Renal gluconeogenesis: its importance in human glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Glucose metabolism in renal tubular function

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Sodium-glucose transporter-2 inhibition as an antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Active sugar transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

21 January 2018

Learning from glycosuria

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Long-term outcome of renal glucosuria type 0: the original patient and his natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Glucose control by the kidney: an emerging target in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

The hypothalamus and ß-cell connection in the gene-targeting era.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Association between serum uric acid and development of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.07.2302

21 January 2018

Identifiers

DOI

10.3810/PGM.2011.07.2302

1 reference

24 August 2017

1 reference